Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.64 |
| ▸ | CA4 | P22748 | 3/20 | 0.64 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.64 |
| ▸ | CA6 | P23280 | 2/20 | 0.64 |
| ▸ | CA5A | P35218 | 2/20 | 0.64 |
| ▸ | CA7 | P43166 | 2/20 | 0.64 |
| ▸ | CA9 | Q16790 | 2/20 | 0.64 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7510213 | 1.00 | CA2 (0.64) | CA2CA4CA1CA12CA6 | |
| SCHEMBL7514823 | 0.95 | CA2 (0.58) | CA2CA4CA1CA12CA6 | |
| SCHEMBL7507808 | 0.95 | CA2 (0.58) | CA2CA4CA1CA12CA6 | |
| SCHEMBL7518760 | 0.94 | CA2 (0.58) | CA2CA4CA1CA12CA6 | |
| SCHEMBL7510619 | 0.94 | CA2 (0.58) | CA2CA4CA1CA12CA6 | |
| SCHEMBL7516535 | 0.92 | CA2 (0.55) | CA2CA4CA1CA12CA6 | |
| SCHEMBL7510317 | 0.92 | CA2 (0.55) | CA2CA4CA1CA12CA6 | |
| Hydrochloric Acid SCHEMBL9597515 | 0.91 | CA2 (0.53) | CA2CA4CA1CA12CA6 | |
| SCHEMBL7506048 | 0.91 | CA2 (0.57) | CA2CA4CA1CA12CA6 | |
| SCHEMBL7509335 | 0.91 | CA2 (0.57) | CA2CA4CA1CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0527801-B1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANHYDRASE INHIBITORS | ALCON LAB INC (US) | 2002-07-31 | — | — | EP | claimed |
| EP-0527801-A4 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | — | 1993-03-10 | — | — | EP | claimed |
| EP-0527801-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1993-02-24 | — | — | EP | claimed |
| WO-1991015486-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1991-10-17 | — | — | WO | claimed |
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230295673-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-09-21 | — | — | US | disclosed |
| US-20220315961-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2022-10-06 | — | — | US | disclosed |
| US-11352609-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210301266-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-09-30 | — | — | US | disclosed |
| US-11060072-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10947572-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3068793-B1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20170268028-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-09-21 | — | — | US | disclosed |
| US-9695451-B2 | Polynucleotides encoding engineered imine reductases | CODEXIS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150080385-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING A CARBONIC ANHYDRASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | PHARMATHEN S.A. (GR) | 2015-03-19 | — | — | US | disclosed |
| WO-2008132114-A1 | PROCESS FOR THE PREPARATION OF BRINZOLAMIDE AND INTERMEDIATES THEREOF | DUKE CHEM, S. A. (ES) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008120099-A1 | THIENO [3, 2-E] [1, 2] THIAZINE DERIVATIVE AS INHIBITOR OF CARBONIC ANHYDRASE | PFIZER INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| EP-0527801-A4 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0527801-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| WO-1991015486-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352609-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | AKR1C4, AKR7A2, AKR1C2 | CA2 4818/4885CA4 4431/4885CA1 4627/4885 |
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | AKR1C4, AKR7A2, AKR1C2 | CA2 4818/4885CA4 4431/4885CA1 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.